Webiomed

What Webiomed does

Webiomed, developed by K-Sky LLC (K-Скай), is a predictive analytics and risk management platform for healthcare built on artificial intelligence and machine learning. Founded in 2018 in Petrozavodsk, Russia, by Alexander Gusev and Roman Novitsky (both Petrozavodsk State University graduates) and operated by a 51-100 person team, the platform ingests anonymized electronic medical record (EMR) data via integrations with Russian Medical Information Systems (MIS), extracts clinical features from unstructured documents using NLP, and applies neural network-based models to predict individual probability of 40+ diseases — including cardiovascular events, cancer, diabetes, and hospitalization. The cardiovascular risk model has been validated at 78% accuracy and AUC 0.77, outperforming the Framingham scale by 19 positions.

The product suite consists of four modules on a shared AI/ML engine: Webiomed.DHRA, a Clinical Decision Support System (CDSS) for physicians providing real-time risk assessment and guideline-based recommendations; WebiomedAnalytics, a management decision-support module for healthcare administrators enabling population-level risk stratification, disease prevalence monitoring, and target tracking; Real Clinical Practice Research (RWD Analysis), a service for pharmaceutical companies analyzing routine clinical data; and Custom ML Model Development for bespoke predictive modeling. The platform has processed over 1 million anonymized electronic medical documents and is operationally deployed across 10+ Russian regions.

Webiomed generates revenue through three streams: subscription or recurring B2G contracts with regional government health authorities (active deployments include Yamalo-Nenets Autonomous Okrug, Kirov Oblast, and Republic of Karelia); professional services and project-based contracts with pharmaceutical companies for real-world data studies (AstraZeneca, Sanofi, Takeda, Roche); and licensing/royalties from MIS vendors that embed Webiomed as an AI module within their systems (RT MIS, K-MIS, Renovacio, and 20+ platforms). Pricing is not publicly disclosed and is negotiated per engagement. The company has accumulated a series of regulatory firsts — first AI registered as a medical device by Roszdravnadzor (April 2020), first AI registered as an "Other Information System" enabling integration with federal EGISZ services (2021), and ISO 13485:2016 certification audited by TÜV AUSTRIA — that materially raise the entry barrier for any domestic competitor.

Name

Webiomed

Legal name

OOO "K-Skay" (ООО «К-Скай»)

Website

https://webiomed.ai

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Webiomed is an AI-powered predictive analytics platform for healthcare that processes anonymized Russian electronic medical records to forecast 40+ diseases, serving regional government health authorities, physicians, pharmaceutical companies (AstraZeneca, Sanofi, Takeda, Roche), and MIS integrators across 10+ regions.

Ownership category

akta.pro rank

Product category

Healthcare AI / Clinical Decision Support Software

NAICS

Software Publishers (5132), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Healthcare Data Quality, Profiling & Observability (HLACAIAE)

akta.pro secondary industries

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), eConsent & Digital Identity for Trials (HLACAOAE)

Keywords

• Predictive healthcare analytics
• Clinical decision support
• Population health management
• Medical AI platform
• Disease risk prediction

Headquarters

HQ city

Petrozavodsk

HQ country

Russia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare Administration / Government B2G: Webiomed is deployed through regional government health programs, where regional administrations and government health authorities purchase access to the platform for use in state-run medical organizations. This is the primary revenue channel, evidenced by deployments in Yamalo-Nenets Autonomous Okrug, Kirov Oblast, and Republic of Karelia.
2. Pharmaceutical Companies - Real-World Data Studies: Webiomed conducts real-world clinical practice studies for pharmaceutical companies (AstraZeneca, Takeda, Sanofi, Roche) using its platform. These engagements involve custom ML model development, data analysis, and research projects, likely billed as professional services or project-based contracts.
3. MIS Integration / OEM Licensing: Webiomed licenses its technology as an embedded module within third-party Medical Information Systems (MIS), such as RT MIS, K-MIS, Renovacio, and others. Revenue is generated through licensing agreements with MIS vendors who embed Webiomed's AI capabilities.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Webiomed is an AI-driven predictive analytics platform for healthcare that ingests anonymized electronic medical records (EMRs) from hospital Medical Information Systems (MIS), extracts medical features via NLP, and applies machine learning to predict individual disease risk, support clinical decisions, and enable population-level health management. The platform operates through two core modules — Webiomed.DHRA (physician clinical decision support) and WebiomedAnalytics (administrator management decision support) — and additionally provides real-world data analysis services for pharmaceutical companies and custom ML model development.

Product overview

Webiomed is a unified predictive analytics platform for healthcare that operates as a modular system. The core platform processes anonymized electronic medical record (EMR) data through AI and machine learning. Four primary modules serve distinct audiences: (1) Webiomed.DHRA — a Clinical Decision Support System (CDSS) for physicians that automates EMR analysis, extracts structured information from unstructured documents, and generates personalized clinical recommendations; (2) WebiomedAnalytics — a management decision support system for healthcare administrators providing population-level risk stratification, disease forecasting, and quality control across regions; (3) Real Clinical Practice Research (RWD) — a research module for pharmaceutical companies analyzing real-world data to find disease predictors and clinical trial candidates; and (4) Custom ML Model Development — a service building bespoke predictive models on demand for clients. All modules share the same AI/ML engine and EMR integration layer.

Differentiator

Problem solved

Functional benefit

Products and services

• Webiomed.DHRA A Clinical Decision Support System (CDSS) for physicians that automatically analyzes electronic medical records (EMRs) using AI, extracts medical information from unstructured documents, identifies disease risk factors, assesses patient risk groups, and generates personalized recommendations for physicians and patients based on clinical guidelines.
• WebiomedAnalytics A management decision support system for healthcare administrators providing population-level analytics, automatic risk-stratification of entire regional populations, disease and mortality forecasting, monitoring of risk factor prevalence, and physician EMR quality control to improve quality of medical care.
• Real Clinical Practice Research (RWD Analysis) A real-world data analysis service for pharmaceutical companies and research organizations that analyzes routine clinical practice data to identify disease predictors, find candidates for clinical trials, evaluate drug therapy effectiveness on high-risk patient populations, and develop custom ML models.
• Custom ML Model Development A bespoke machine learning model development service for pharmaceutical companies, insurance companies, and research organizations that builds custom predictive models on medical data to address specific research or business objectives.

Quantifiable outcome

• Cardiovascular disease prediction model accuracy of 78%, AUC 0.77 — outperforming the Framingham scale by 19 positions in accuracy
• +4 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature7 records

Partnerships

14 partnerships are on record, tiered core, major and minor.

• RT MIS (РТ МИС, RT Medical Information Systems)coreTechnology or Integration · 19 April 2021RT MIS, the leader in medical information systems in Russia (part of Rostelecom Group), signed a cooperation agreement with K-Sky in AI. The partnership enables integration of Webiomed's AI platform with RT MIS's medical information systems deployed across Russian medical organizations, creating a key distribution channel.
• AstraZenecacoreStrategic or Co-development Partner · 17 January 2021AstraZeneca and K-Sky signed a memorandum on joint implementation of the project 'Improving diagnosis of chronic kidney disease through development and introduction of a physician decision support system'. This is a separate formalized partnership between the international pharma company and Webiomed.
• SanofimajorStrategic or Co-development Partner · 30 October 2020Webiomed was one of 3 winners of the Sanofi innovation competition in healthcare jointly organized with Skolkovo Foundation. The collaboration focuses on developing solutions for patients with chronic diseases and leveraging big data management in healthcare.
• RochemajorStrategic or Co-development Partner · 16 October 2020Webiomed won the 'Personalized Medicine' special nomination from Roche at the Startup Rally 2020 competition. Roche's interest in Webiomed relates to personalized medicine approaches using real-world clinical data.
• AstraZeneca RussiacoreStrategic or Co-development Partner · 2 July 2020Webiomed won the commercial track of AstraZeneca Skolkovo StartUp Challenge 2020 and signed a memorandum for joint implementation of a project on 'Improving diagnosis of chronic kidney disease through development and implementation of a clinical decision support system'. The partnership involves real-world data studies and clinical decision support development.
• Skolkovo Foundation (Фонд Сколково)coreStrategic or Co-development Partner · 1 August 2019Webiomed has been a resident of the Skolkovo Foundation's biomedical technologies cluster since August 2019. Skolkovo provides funding support, access to the startup ecosystem, and facilitates partnerships with large corporations and government. Webiomed won multiple competitions organized by Skolkovo (MedLAB, Future Healthcare accelerator, etc.) and benefits from the foundation's networking and business development support.
• Petrozavodsk State University (ПетрГУ)coreStrategic or Co-development PartnerWebiomed was co-founded by graduates of Petrozavodsk State University. The company collaborates with the university on joint scientific research in AI and digital health technologies, AI laboratory in medicine at the university's medical institute, and dataset creation for research. The university also serves as a scientific advisor.
• TakedamajorStrategic or Co-development PartnerTakeda is mentioned alongside AstraZeneca and Sanofi as one of the pharmaceutical giants for whom Webiomed conducts real-world clinical practice studies using its platform, supporting drug development and market research.
• Sechenov University (Сеченовский университет)majorStrategic or Co-development PartnerListed as a partner, indicating collaboration on scientific research, clinical validation, and potentially academic publication related to Webiomed's technology.
• National Base of Medical Knowledge (Национальная база медицинских знаний, NBMZ)majorStrategic or Co-development PartnerCo-founded by Alexander Gusev in 2018, NBMZ is an association of AI developers and users in medicine. Webiomed participates in joint activities with NBMZ including the Ethics Code for AI in medicine. NBMZ helped develop regulatory recommendations for AI medical device registration.
• Federal Scientific and Clinical Center for Specialized Types of Medical Assistance and Medical Technologies (FMBC)minorStrategic or Co-development PartnerListed as a partner; may relate to clinical validation and expert consultation on Webiomed's medical technology.
• Center for Medical Prevention of Yamalo-Nenets Autonomous OkrugmajorStrategic or Co-development PartnerLong-standing implementation partner for Webiomed pilots in the Yamalo-Nenets region, conducting preventive medicine programs using Webiomed's AI.
• K-MIS (К-МИС)majorTechnology or IntegrationK-MIS, co-founded by the same founders of Webiomed, is a leading developer of medical information systems in Russia. It serves as a key channel for embedding Webiomed's AI capabilities within the K-MIS ecosystem of medical organizations.
• Agency for Strategic Initiatives (АСИ)minorStrategic or Co-development PartnerListed as a partner; ASI supports innovative projects in Russia and partnered with Webiomed through its 'The Country is Changed by People' prize.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• SberMedII (Sber Health AI): Sberbank's healthcare AI subsidiary developing clinical decision support, medical imaging, and predictive analytics for the Russian market. It is the most direct competitor to Webiomed in Russian AI healthcare, with the financial backing of Sber to outspend Webiomed on R&D and government contracts.
• Botkin.AI: Russian medical AI company focused on predictive analytics and clinical decision support using medical imaging and EMR data. Competes directly with Webiomed for regional Russian health authority contracts and pharma AI partnerships.
• Celsus (MDDC): Russian medical AI platform initially focused on radiology but expanding into broader clinical decision support. It is part of the Larta Group/Philips ecosystem and competes with Webiomed for B2G contracts and hospital MIS integrations in Russia.

Broad incumbents

• Tempus AI: U.S. AI-powered precision medicine company providing multi-modal data, RWD analytics, and clinical decision support to pharma and providers. Comparable because it sells similar pharma RWD/custom ML services to AstraZeneca/Pfizer-style customers, albeit at vastly larger scale.
• IQVIA: Global clinical research and real-world data giant serving pharma R&D with EDC, RWD, and AI-driven evidence generation. Comparable as a benchmark for the pharma RWD/services revenue stream Webiomed is cultivating with AstraZeneca/Sanofi/Roche/Takeda.
• Flatiron Health: Oncology-focused EHR data and RWD platform acquired by Roche, providing curated clinical data and AI analytics to pharma and providers. Comparable to the pharma RWD and oncology risk-prediction modules in Webiomed's portfolio.

Emerging players

• Health Catalyst: U.S. healthcare data and analytics enterprise platform for population health, quality, and risk stratification. Comparable to WebiomedAnalytics in serving healthcare administrators with population-level decision support and risk stratification.
• Innovaccer: Healthcare data platform unifying EHR/claims and providing AI-driven population health management and risk stratification. Overlaps with WebiomedAnalytics in delivering population-level risk stratification and management decision support.
• Truveta: RWD platform aggregating de-identified EHR data across U.S. health systems for pharma research and AI model development. Closely comparable to Webiomed's pharma RWD engine and its real-world clinical practice research product.
• Owkin: AI-for-medical-research company applying federated learning to clinical and biological data for pharma R&D. Comparable to Webiomed's custom ML model development and clinical research collaborations with pharma (AstraZeneca, Sanofi, Roche).

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCObOwO7A_F_LG-DxcCNNFrg/featured
• Xx.com/webiomed
• Facebookfacebook.com/webiomed

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Webiomed